Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: Mary Stewart mstewart@entnet.org 703-535-3762 American Academy of Otolaryngology - Head and Neck Surgery

Alexandria, VA Genetic testing for a certain mutation in pediatric patients is valuable in determining a cause for unexplained hearing loss, according to a study in the November 2012 issue of OtolaryngologyHead and Neck Surgery.

The study's authors state that testing for some of the most common mutations that cause sensorineural hearing loss in a targeted way, rather than through generalized screening of hearing loss patients, yields the best results.

University of Miami NIH-funded researchers led by Dr. Xue Zhong Liu, a physician-scientist, conducted a nine-year study on 221 adult and 163 pediatric patients with sensorineural hearing loss. Blood samples were screened for mutations in GJB2 and GJB6 and mitochondrial DNA mutations, audiometric tests were conducted, and patient and family histories were taken.

Mutations in the GJB2/GJB6 genes were identified in 23 of 163 pediatric patients (14%), but only 3 of 221 adults (1%). Thirteen percent of the pediatric patients were determined to be carriers. The mitochondrial testing in adults returned a higher rate (3%) than what is usually reported (1%). Identifying DFNB1 mutations early will provide carriers with a number of options, including risk factor avoidance and pharmaceutical options to prevent hearing loss from progressing or improving existing conditions.

The authors conclude, "Our study supports the considerable value of genetic testing in establishing an etiology for childhood hearing loss. Given its high yield, DFNB1 mutation screening should be considered an early step in the diagnostic evaluation of pediatric hearing loss. However, its role in adults seems considerably more limited and is yet to be defined."

###

OtolaryngologyHead and Neck Surgery is the official scientific journal of the American Academy of OtolaryngologyHead and Neck Surgery Foundation (AAO-HNSF). The study's authors are Peter J. King, MD; Xiaomei Ouyang, MD; Lilin Du; Denise Yan, PhD; Simon I. Angeli, MD, and corresponding author, Xue Zhong Liu, MD, PhD.

Reporters who wish to obtain a copy of the study, "Etiologic Diagnosis of Nonsyndromic Genetic Hearing Loss in Adult vs Pediatric Populations" should contact Mary Stewart at 1-703-535-3762, or newsroom@entnet.org.

See original here:
Etiologic diagnosis of nonsyndromic genetic hearing loss in adult vs pediatric populations

Recommendation and review posted by Bethany Smith

Q. What is genetic fingerprinting? How valuable is it in crime investigations and tracing one's parentage?

--mar_g2009@yahoo.com

A. Genetic fingerprinting (DNA testing; DNA typing; DNA profiling) refers to the process of identifying an individual by studying his DNA. DNA is short for deoxyribose nucleic acid, a molecule that can be found in the nucleus of each and every cell of the body, except for the red blood cells which do not have a nucleus.

In the nucleus, the DNA molecules are contained in structures called chromosomes, of which there are 23 pairs in humans. Half of the 23 pairs of chromosomes that a person has have been inherited from his/her mother and the other half from his/her father.

The DNA molecule in each chromosome is in the form of a very long but thin thread that consists of two twisted strands made up of sugar and phosphate molecules. At regular intervals, nitrogen-containing bases connect the two strands to each other-much like the two-sides of a ladder being connected by rungs.

The human genome, which refers to the total amount of DNA present in the 23 pairs of chromosomes, contains three billion nitrogen bases. The sequencing or arrangement of these bases (DNA sequence) in the DNA strands within the chromosomes is unique to a person. The probability that two living persons have identical DNA sequence (except for identical twins) is practically zero. The complicated process of development that the egg cell (of a person's mother) and the sperm cell (of a person's father) undergo before these two cells unite during fertilization to produce the fetus that will eventually become the person ensures this.

Genetic fingerprinting involves obtaining segments of a person's DNA from certain chromosomes and comparing the sequence of the bases in these segments with those of another person or particular population or family groups and identifying DNA sequences, called genetic markers, which the person have in common with the others. Statistical analysis of this comparison can help resolve questions regarding a person's ancestry and help forensic investigators solve crimes. Incidentally, for samples, genetic fingerprinting utilizes nucleated body cells, which can come from any body tissue such as a single root of hair, saliva, urine or semen.

Genetic fingerprinting is a more accurate method of identification than fingerprinting, blood typing or any other procedure that is presently being employed. But in its current state of development, genetic fingerprinting has limited applications. In forensic medicine, it is useful in acquitting innocent suspects, but not in convicting guilty ones. The test cannot tell whether the DNA sample taken from the crime scene comes from the suspect, but it can tell with certainty if it does not come from the suspect.

Similarly, in verifying the parentage of a child, genetic fingerprinting cannot definitely say whether the person who is undergoing the test is the mother or father of a child, but it can tell with certainty if he or she is not the parent.

Genetic fingerprinting also has other advantages over other identification procedures. Because DNA is resistant to degradation, genetic fingerprinting can still be done even if the sample has been treated with detergents, acids, bases, oil-based products, salt, and even if it has been contaminated by bacteria. Additionally, DNA degrades very slowly hence, samples that are already several years old or those taken from corpses that have been buried for years can still be used.

See the original post here:
The world of genetic fingerprinting

Recommendation and review posted by Bethany Smith

Size Genetics
bit.ly Size genetics is a natural way of male enlargement using the age old technique of traction to extend the penis. The penis extender has been around for some years, and the technology has come a long way. Extenders are now developed with comfort in mind, and Size Genetics offers the best system for this. They have now what #39;s called a 16 way comfort system that caters to each individuals needs. No other penis extender system offers as much as SizeGenetics. Click the link above to read my personal review of the size genetics system.From:Tom CarnegyViews:2 0ratingsTime:01:11More inHowto Style

See original here:
Size Genetics - Video

Recommendation and review posted by Bethany Smith

Netpak Promo video Ang
Netpak, a new breed in high performance packaging and responsible printing. Newest technology, service, expertise and innovation. That is the genetics of NetpakFrom:emballagesnetpakViews:0 0ratingsTime:02:59More inPeople Blogs

Continue reading here:
Netpak Promo video Ang - Video

Recommendation and review posted by Bethany Smith

How To Stick To A Diet - Part 4 Goals
excuseproof.com - Want to know how to stick to a diet? Need more motivation to stick to a healthy diet plan? Learn how to get motivated to stay on your diet using the latest findings of modern psychology and neuroscience in this on-going video series. If you don #39;t know what you want, how are you going to get there? In this video, we #39;re going to finish up the "awareness" aspect by figuring out what you want that a better diet will bring you. It could be a fitter body, more energy, better health, or all of the above. Goal writing tips Use a pen and paper (do this by hand) for a stronger neural connection Write in present tense as if you already have reached your goals Write the positive emotions you would be feeling Write what you #39;ll HAVE, what you #39;ll DO, and how you #39;ll see yourself BEING What you have is a result of what you do which is a result of who you are or perceive yourself to be. In upcoming videos you #39;ll learn: Why willpower alone doesn #39;t work, and what the proper role of willpower really is. Which "force" is stronger than willpower. When goals can actually be detrimental to success and what their purpose is. How to rewire your brain and reprogram your genetics. How you can overcome and stop junk food cravings. What the biggest mistake people make is when starting a diet. How you can change your habits permanently, even if you #39;ve had them your entire life. Tons more! For more dieting and healthy living tips, check out: "How To Stick To A Diet" kindle book www ...From:ExcuseProofViews:0 0ratingsTime:03:57More inHowto Style

See original here:
How To Stick To A Diet - Part 4 Goals - Video

Recommendation and review posted by Bethany Smith

ViolinistThumb_ch1a
Introducing genetics pioneer - Friedrich Miescher. First part of Chapter 1, "The violinist thumb" by Sam Kean. How do living things pass down traits to their children.From:TokyoBookWormViews:0 0ratingsTime:00:26More inFilm Animation

Follow this link:
ViolinistThumb_ch1a - Video

Recommendation and review posted by Bethany Smith

GHOST ISLAND (The Hidden) !
Download full: ftpgood.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage: Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments were destroyed. Infinitum Research denies all knowledge of ...From:ardanx9Views:1 0ratingsTime:03:17More inEntertainment

More here:
GHOST ISLAND (The Hidden) ! - Video

Recommendation and review posted by Bethany Smith

Genetics by Design Sale
Genetics by Design SaleFrom:TheHolsteinWorldViews:0 0ratingsTime:01:56More inPets Animals

Follow this link:
Genetics by Design Sale - Video

Recommendation and review posted by Bethany Smith

"Rob" singing to Jono #39;s trumpet playing
The red white Border Collie pup "Rob" we are currently fostering also is trying to sing along with Jono (sounds more like barking - but he really is trying to sing) ... shares genetics with Teine...he too has the "singing gene"From:Richard MitchellViews:4 0ratingsTime:00:28More inPets Animals

Excerpt from:
"Rob" singing to Jono's trumpet playing - Video

Recommendation and review posted by Bethany Smith

Life and Learning Systems (4) - Co-evolution of Language and Brain_short.avi
This is the shortened version of the 4th video in the Life and Learning Systems series. In this video I introduce Terrence Deacon #39;s idea of how relaxed selection could have played a role in weakening the constraints of genetics and accelerated the brain #39;s evolution, in particular as it relates to the brain #39;s symbolic capacity. This is the first video in this series to begin examining symbolic capacity, and as an extension linguistic capacity, and how this capacity is dependent upon elements external, yet connected, to the body. Notes: docs.google.com Presentation: docs.google.comFrom:morellidjejuViews:1 0ratingsTime:16:39More inEducation

Excerpt from:
Life and Learning Systems (4) - Co-evolution of Language and Brain_short.avi - Video

Recommendation and review posted by Bethany Smith

High-throughput phenotyping at The Plant Accelerator®
The Plant Accelerator, headquarters of the Australian Plant Phenomics Facility, was built to help alleviate the phenotyping bottleneck and accelerate advances in crop physiology and genetics. It houses fully automated imaging and watering systems, allowing large scale phenotypic screens under various stress conditions, such as salinity or water stress. Important traits, such as relative growth rate or water use efficiency can be measured non-destructively over time in a throughput that allows genetic screenings.From:LemnaTec2008Views:0 0ratingsTime:20:01More inScience Technology

View post:
High-throughput phenotyping at The Plant Accelerator® - Video

Recommendation and review posted by Bethany Smith

Genetics-Iran-11-04-2012
Iranian scientists have been working in the field of genetics for half of a century. Today the institute of genetic engineering and biotechnology is one of the leading research centers in the region. Its activities are aimed at enhancing the quality of life by better food medicine and environment. Amir Mehdi Kazemi reports on genetic engineering and biotechnology in Iran. Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.comFrom:FullWorldNewsViews:0 0ratingsTime:06:41More inNews Politics

See the article here:
Genetics-Iran-11-04-2012 - Video

Recommendation and review posted by Bethany Smith

Evolution - Occam #39;s razor
"Rejecting evolution expresses more than an inability to think critically; it relies on a fundamentally paranoid worldview. Think what the world would have to be like for evolution to be false. Almost every scientist on earth would have to be engaged in a fraud so complex and extensive it involved every field from archaeology, paleontology, geology and genetics to biology, chemistry and physics. And yet this massive concatenation of lies and delusion is so full of obvious holes that a pastor with a Bible-college degree or a homeschooling parent with no degree at all can see right through it." Source: http://www.patheos.com Music is Mozart #39;s Eine Kleine Nachtmusik, Second MovementFrom:TryzonUncutViews:0 0ratingsTime:00:33More inEducation

Follow this link:
Evolution - Occam's razor - Video

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that its collaborator, Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced that the European Commission has granted conditional marketing authorization for ADCETRIS (brentuximab vedotin). ADCETRIS was approved for two indications: (1) the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). As a result, under the collaboration Seattle Genetics will receive two milestone payments from Millennium, one for each indication, totaling $25 million. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.

The approval of ADCETRIS by the European Commission marks a significant milestone for the product and for the many relapsed or refractory HL and systemic ALCL patients in need of effective new treatment options in Europe, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. In addition to the U.S. and EU approvals of ADCETRIS, we are making regulatory progress for approval in Canada while Millennium and Takeda are pursuing regulatory approvals in other countries. Complementing these regulatory activities is a robust ADCETRIS clinical development program to support our goal of establishing it as the foundation of therapy for CD30-positive malignancies.

The conditional marketing authorization for ADCETRIS is valid in the 27 member states of the European Union (EU) as well as Norway, Liechtenstein and Iceland. Similar to accelerated approval regulations inthe United States, conditional marketing authorizations are granted in the EU to medicinal products that fulfill an unmet medical need with a positive benefit/risk assessmentand whose immediate availability would result in a significant public health benefit. Conditional marketing authorization by the European Commission includes obligations to provide additional clinical data at a later stage to confirm the positive benefit-risk assessment. The ADCETRIS Marketing Authorization Application was filed by Takeda Global Research & Development Centre (Europe) to the European Medicines Agency.

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2011 for relapsed HL and sALCL.

Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs. Seattle Genetics is entitled to royalties based on a percentage of Millennium's net sales in its territory at rates that range from the mid-teens to the mid-twenties based on sales volume, subject to offsets for royalties paid by Millennium to third parties.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The FDA granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at http://www.seattlegenetics.com.

Read more:
Seattle Genetics Announces ADCETRIS® Receives European Commission Conditional Marketing Authorization

Recommendation and review posted by Bethany Smith

Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: Ben Norman Sciencenewsroom@wiley.com 44-124-377-0375 Wiley

John Wiley & Sons, Inc., today announced the launch of Molecular Genetics & Genomic Medicine (MGGM), a new Wiley Open Access journal. Under the leadership of Editor-in-Chief Dr. Maximilian Muenke, the journal will provide rapid dissemination of high-quality research in all areas of human, medical and molecular genetics.

Dr. Muenke, a renowned medical geneticist, trained in pediatrics in his native Germany and then pursued postdoctoral fellowship training in human and clinical genetics at Yale and the University of Pennsylvania. He is now based at a leading research organization in Bethesda, USA.

Dr. Muenke's group identified several genes important in craniofacial disorders including one of the most common, now termed Muenke syndrome. More recently, his lab has identified susceptibility genes for the most common childhood behavioral disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), with further research focused on predicting severity, treatment, and long-term outcome.

Working alongside an international editorial board of experts in diverse areas of human and medical genetics and genomics, Dr. Muenke will oversee the rigorous peer-review and evaluation of articles submitted for publication in MGGM.

"I am extremely excited about being the founding editor of this new journal," says Dr. Muenke. "Since there is not a single disorder that does not have a genetic origin, I believe that the fields of molecular genetics and genomic medicine will be expanding into virtually all medical specialties. MGGM will grow as well, with articles on diseases from diagnosis to treatment, as a step toward personalized medicine. "

Molecular Genetics & Genomic Medicine is the latest addition to Wiley's portfolio of genetics journals and will benefit from relationships with widely respected titles including the American Journal of Medical Genetics and Human Mutation.

"We're delighted to expand our open access portfolio with the addition of this important new journal," said Rachel Burley, Vice President and Director, Open Access, Wiley. "Under the expert editorial leadership of Dr. Muenke, Molecular Genetics & Genomic Medicine will make a valuable contribution to the literature."

###

Continue reading here:
Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley

Recommendation and review posted by Bethany Smith

LOS ANGELES, Nov. 5, 2012 /PRNewswire/ --Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements. Recently, the Massachusetts General Hospital Cancer Center ("MGH") published studies showing that ROS1 driven tumors are sensitive to the FDA approved drug XALKORI1 (crizotinib)2 to treat non-small-cell lung cancer ("NSCLC") patients with ALK gene rearrangements. Tumors driven by rearrangements in the ROS1 gene represent an additional 1 to 2 percent of patients who may be candidates for crizotinib therapy.3 The company will offer both fluorescence in situ hybridization ("FISH") and polymerase chain reaction ("PCR") based ROS1 translocation testing.

"We are pleased to add ROS1 to our growing test menu," said Thomas Bologna, chairman and CEO of Response Genetics. "We believe the dual option of FISH and PCR represent a unique offering and is consistent with our Leave No Stone Unturned program whereby we go to great lengths to help patients receive optimal therapy. While FISH is the technology that has been used for ROS1 to date, PCR has the advantage of providing additional information about the variant found, information that may be useful for evaluating response and resistance mechanisms.This promising new marker is now readily available to pathologists and oncologists seeking fast turnaround time and utilizes the company's proprietary methods that enable results on very small biopsies including fine needle aspirates."

ROS1 supplements the company's recently introduced Leave No Stone Unturned program, in which patients whose tumors test negative for the ALK Break Apart FISH assay receive follow-up ALK testing using the company's proprietary EML4-ALK RT-PCR-based assay at minimal additional cost. With the addition of ROS1, ordering clinicians can now make a more complete evaluation of each of their NSCLC patients as candidates for crizotinib therapy.

1 XALKORI is a registered trademark of Pfizer, Inc. 2 Bergethon et. al. "ROS1 rearrangements define a unique molecular class of lung cancers." Journal of Clinical Oncology 2012 Mar 10;30(8):863-70. Epub 2012 Jan 3. 3 Ibid

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomics testing services of clinical-trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, and to continue to execute on its business strategy and operations, to continue to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Originally posted here:
Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that more than a dozen abstracts, in addition to several collaborator abstracts, for both ADCETRIS (brentuximab vedotin) and investigational antibody-drug conjugates (ADCs) will be presented at the American Society of Hematology (ASH) Annual Meeting taking place in Atlanta, Georgia, December 8 11, 2012. ADCETRIS is an ADC directed to CD30, which is known to be expressed in Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), as well as in some types of cutaneous T-cell lymphoma (CTCL), B-cell lymphomas and mature T-cell lymphomas (MTCL). Seattle Genetics is broadly evaluating CD30 expression in many other cancer types. ADCETRIS is currently not approved for use in CTCL, B-cell lymphomas, and front-line treatment of HL or MTCL.

"The comprehensive data presented at ASH 2012 support our goal to establish ADCETRIS as the foundation of therapy for a broad array of CD30-positive malignancies and redefine therapy in the front-line setting of HL and MTCL, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "As a pioneer in developing ADC therapies, we continue to innovate by expanding the ADCETRIS program into CD30-positive malignancies, advancing additional ADC pipeline candidates, and supporting the progress of our collaborator ADC programs. These important advances represent our continued innovation and ADC leadership position."

Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Of the approximately 30 ADC candidates currently in development, more than half utilize Seattle Genetics proprietary ADC technology. Multiple company, investigator and collaborator presentations will be presented at ASH, including data on ADCETRIS in many types of CD30-positive malignancies and preclinical data from a new ADC product candidate called SGN-CD33A. Abstract presentations planned at ASH can be found at http://www.hematology.org and include the following:

ADCETRIS Data in the Front-line Setting

ADCETRIS Data in CTCL

ADCETRIS Data in Hodgkin and Non-Hodgkin Lymphomas

Data on Other ADC Candidates and Collaborator Programs

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Read more from the original source:
Seattle Genetics’ ASH 2012 Presentations Highlight ADCETRIS® and Demonstrate Leadership in the Development of Antibody ...

Recommendation and review posted by Bethany Smith

LOS ANGELES, Nov. 6, 2012 /PRNewswire/ --Response Genetics, Inc. (RGDX),a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce its third quarter financial results and give an operational update in a press release to be issued before the market opens on Tuesday, November 13, 2012. The company will host a conference call that same day at 10:00 a.m. EST to discuss its financial results.

Conference Call Details

To access the conference call by phone on November 13 at 10:00 a.m. EST, dial (800) 537-0745 or (253) 237-1142 for international participants. A telephone replay will be available beginning approximately two hours after the call through November 20, and may be accessed by dialing (855) 859-2056 or (404) 537-3406. The conference passcode for both the live call and replay is 57580014.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the Company's website at http://investor.responsegenetics.com. It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Read this article:
Response Genetics, Inc. to Release Third Quarter Financial Results and Host Conference Call on November 13, 2012

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Metamark Genetics, Inc., a privately held, oncology-focused molecular diagnostics company, announced today that it has closed a $13 million series B financing led by current and new private investors. The proceeds from this round will enable the company to further refine its novel, protein-based prostate cancer prognostic tests and complete final clinical validation work. The company is developing two separate prognostic tests. The first is designed to use prostate cancer biopsy tissue to help physicians more accurately determine if patients have a slow-growing or aggressive form of prostate cancer, thereby improving treatment decisions. The second is designed to predict the longer-term course of disease.

This new funding comes on the heels of Metamark successfully completing important proof-of-concept work last spring, said Kenneth Weg, Metamark co-founder and founding chairman of the board of directors. This enables us to proceed with diagnostic and drug target research at an accelerated rate and moves us closer to our goal of achieving commercialization of the Metamark prostate cancer test.

Leadership and board appointments

In conjunction with closing the financing, the company announced changes to the board of directors and the resignation of Mark Straley as president and CEO. Straley resigned to pursue other opportunities and Metamark is conducting a search for a new CEO to lead the company into commercialization and further development.

Michael Kauffman, M.D., Ph.D., joined the Metamark Genetics board of directors and will serve as interim executive director until a new company president and CEO is appointed. Kauffman was vice president of medicine and an early employee at Millennium Predictive Medicine, the diagnostics and pharmacogenomics arm of Millennium Pharmaceuticals Inc. where he co-led collaborations with Becton Dickinson and Bristol-Myers Squibb. More recently, Dr. Kauffman co-founded Karyopharm Therapeutics, a pharmaceutical company developing novel oncology drugs. He was previously chief medical officer of Proteolix Pharmaceuticals and Onyx Pharmaceuticals Inc., where he oversaw the clinical development of carfilzomib. He received his M.D. and Ph.D. from Johns Hopkins Medical School and is board certified in internal medicine.

Greg Critchfield, M.D., M.S., was appointed as lead director of the board. Dr. Critchfield has served on the Metamark board since September 2010. Previously he served as president and board member of Myriad Genetic Laboratories, Inc., the diagnostic subsidiary of Myriad Genetics, Inc., where he was responsible for building scientific, medical, and commercial capabilities and launching seven novel molecular diagnostic products across a variety of technology platforms. Prior to Myriad, he served as chief medical and science officer with responsibility for science, medicine, and innovation at Corning Clinical Laboratories, which later became Quest Diagnostics, Inc. Dr. Critchfield received a bachelor's degree in Microbiology with a minor in Chemistry from Brigham Young University, a M.D. degree from the University of Utah, and a master's degree in Biophysical Sciences at the University of Minnesota. He currently serves as CEO of Sera Prognostics, Inc., and is an independent director of a number of innovative life sciences companies.

Commenting on the leadership changes, Dr. Critchfield stated, Mark has led the company to achieve critical clinical and commercial milestones and we thank him for his contributions and wish him the very best with his future endeavors. He continued, During this time of transition, we are pleased to have Kens continued leadership on our board. He has served as board chairman since the company was formed and has been a rallying foundation for the company. We also feel fortunate to have an individual of Michaels talents and accomplishments serve in this interim leadership capacity as we complete validation of the strong clinical diagnostics foundation built by the Metamark Founders and employees.

About Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of molecular function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamarks proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the companys website at http://www.metamarkgenetics.com.

Continued here:
Metamark Genetics Completes $13 Million Series B Financing; Announces Leadership Changes

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced results for its first fiscal quarter ended September 30, 2012. Revenue for the first fiscal quarter increased 21 percent over the same period in the prior year to $133.4 million. First fiscal quarter earnings per diluted share were $0.36, an increase of 24 percent over the same period of the prior year.

"In what has historically been a challenging summer quarter, Myriad achieved record revenue and higher operating profits," said Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We believe that our initiatives of growing existing tests and markets have fueled these strong financial results and we continue to be excited about the future potential contributions from our strategic directives of expanding internationally and launching new tests across a diverse set of major disease indications."

First Fiscal Quarter 2013 Results

Business Highlights during the First Quarter of Fiscal 2013

Fiscal Year 2013 Outlook

The Company has increased its expectations for fiscal year 2013 financial performance. Total revenue is now expected to be in a range of $570 million to $585 million, an increase from the original fiscal 2013 guidance of $550 million to $565 million. This level of revenue is expected to result in diluted earnings per share of $1.50 to $1.55, up from the original guidance of $1.44 to $1.48 per share. An important part of the Company's customer base in the Eastern United States has been affected by the recent severe storm. Although the impact of this event on the Company's future revenues is not yet determinable, it believes that the effect will be short-term in nature and the potential impact was considered in the revised fiscal year 2013 outlook. These projections are forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. The Company will provide further detail on its business outlook during the conference call it is holding today to discuss its fiscal 2013 first quarter financial results.

Conference Call and Webcast

A conference call will be held on Monday, November 5, 2012, at 4:30 p.m. Eastern Time to discuss Myriad's financial results for the first fiscal quarter of 2013. The dial-in number for domestic callers is (800) 354-6885. International callers may dial (303) 223-2680. All callers will be asked to reference reservation number 21607424. An archived replay of the call will be available for seven days by dialing (800) 633-8284 and entering the reservation number above. The conference call will also be available through a live Webcast at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Excerpt from:
Myriad Genetics Reports First Quarter Fiscal Year 2013 Results

Recommendation and review posted by Bethany Smith

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) announced today that it will host a conference call and Webcast on Wednesday, November 14, 2012 at 4:30 p.m. ET to discuss the Companys third quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.s Website at http://www.ilgenetics.com.

About Interleukin Genetics Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Originally posted here:
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2012 Results

Recommendation and review posted by Bethany Smith

James Bond - Die Another Day Watch Online Free, part 1 of 7, full lenght movie
James Bond - Die Another Day In the pre-title sequence, James Bond and his two South Korean allies infiltrate a North Korean military base belonging to Colonel Tan-Sun Moon, an army officer who is illegally selling weaponry in exchange for African conflict diamonds. Bond poses as a weapons dealer, rigging his briefcase of diamonds with C4. He meets Moon and his assistant, Zao. After the diamonds are handed over, Zao discovers Bond #39;s true identity and informs Moon. Fearing retribution from his father, General Moon, the Colonel then flees in a large hovercraft. Bond detonates the C4, embedding several diamonds in Zao #39;s face. He then steals another hovercraft and chases Moon, who tumbles into a waterfall. Soon after, North Korean troops capture Bond under General Moon #39;s orders and he is imprisoned and tortured. Fourteen months later, Bond is released in exchange for Zao, who was captured during that time. He is sedated and taken to meet M, who informs him that his status as a 00 Agent is suspended due to her belief that he may have leaked information under duress. Still bitter over Zao #39;s release, Bond decides to complete his mission by evading MI6 #39;s security and travels to Cuba. He traces Zao to an island called Isla Los Organos, known for its gene therapy "Clinic" which allows patients to have their appearances changed. On the coast, he meets a NSA agent Giacinta #39;Jinx #39; Johnson. With her help, Bond locates Zao #39;s room inside the clinic and briefly tortures him. Zao flees in aFrom:glasefclerko1986Views:0 0ratingsTime:04:06More inEntertainment

Follow this link:
James Bond - Die Another Day Watch Online Free, part 1 of 7, full lenght movie - Video

Recommendation and review posted by Bethany Smith

Lysosomal Storage Disorders
ll4.me Lysosomal Storage Disorders From Lysosomes to Storage Diseases and Back: A Personal Reminiscence.- Lysosomal Biogenesis and Disease.- The Concept of Treatment in Lysosomal Storage Diseases.- Complex Lipid Catabolism.- Retroviral Vectors for Gene Therapy.- Adenovirus in Gene Therapy.- Setting Back the Clock: Adenoviral-Mediated Gene Therapy for Lysosomal Storage Disorders.- Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders.- Herpes Simplex Virus Vectors for Gene Therapy of Lysomal Storage Disorders.- Gene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors.- Substrate Reduction Therapy.- Newborn Screening for Lysosomal Storage Disorders.- Genetic Counseling for Lysosomal Storage Diseases.- Neural Stem Cell Therapy in Lysosomal Storage Disorders.- The GM1 Gangliosidoses.- The GM2 Gangliosidoses.- Acid Sphingomyelinase-Deficient Niemann-Pick Disease.- Krabbe Disease (Globoid Cell Leukodystrophy).- Metachromatic Leukodystrophy.- Fabry Disease.- Gaucher Disease: Review and Perspectives on Treatment.- Therapeutic Goals in the Treatment of Gaucher Disease.- The Neuronal Ceroid Lipofuscinoses: Clinical Features and Molecular Basis of Disease.- Mucopolysaccharidosis I.- Mucopolysaccharidosis II.- Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies.- Mucopolysaccharidosis IV (Morquio Syndrome; MPS IV).- Mucopolysaccharidosis Type VI (MPS VI, Maroteaux-Lamy Syndrome).- Mucopolysaccharidosis Type VII (Sly Disease): Clinical, Genetic ...From:davidbrown9865Views:0 0ratingsTime:00:13More inPeople Blogs

View original post here:
Lysosomal Storage Disorders - Video

Recommendation and review posted by Bethany Smith

CF Gene Therapy
News clip on new gene therapy shot coming next year to treat CF possibly...From:AH FrenchViews:0 0ratingsTime:02:25More inEducation

View original post here:
CF Gene Therapy - Video

Recommendation and review posted by Bethany Smith

The world's first mass-market gene therapy has been legalized in Europe. Glybera, which treats a painful disorder that leads to pancreatitis, will be available in hospitals beginning next year.

Chances are you haven't heard much about lipoprotein lipase deficiency (LPLD), a disease that leads to pancreatitis. This rare disease, however, is at the center of world-changing medical advances.

Last week the European Union approved a gene therapy treatment for LPLD--and this marks the first time any medical treatment that rewrites a patients' DNA has been approved for commercial use.

The treatment, called Glybera, will be released by Dutch firm uniQure in the second half of 2013. Glybera will be administered to patients by specially trained doctors at a limited number of European hospitals. Patients receiving treatment have their DNA altered by a series of injections into their leg muscles, which helps normalize the metabolism of fat particles carried in the blood. LPLD prevents sufferers from properly metabolizing these particles, leading to a host of side effects including pancreatitis.

Gene therapy is an emerging form of medicine, focusing on the use of DNA to rewrite or supplement existing genes. This experimental practice is expected to lead to a series of breakthroughs over the next 50 or so years for various types of cancers, Parkinson's disease, sickle cell anemia, and a host of inherited conditions. Studies involving different forms of gene therapy are currently under way in Europe and the United States--one famous case in 2007 involved a man who was cured of HIV through stem cell transplantation. Stem cell transplants are one type of gene therapy used to give patients therapeutic DNA; other methods use different sources.

LPLD affects approximately one in 1,000,000 people worldwide. Apart from (frequently fatal) acute pancreatitis, patients regularly suffer from yellow spots on their skin, swollen abdomens, enlarged livers, severe abdominal pain, and diarrhea. The condition is currently treated through diet--patients are encouraged to go on a strict low-fat, alcohol-and-red-meat-free diet to mitigate symptoms.

By helping to normalize the metabolism of fat, Glybera prevents inflammation of the pancreas thereby averting the associated pain and suffering and, if administered early enough, the associated co-morbidities, said Professor John Kastelein of the University of Amsterdam in a statement.

Gene therapy treatments in the United States are primarily focused on cancer, including leukemia. No other gene therapy products are expected to be approved by major medical regulator agencies in 2012. The European Commission, which handles medical approvals for Europe, is widely considered to have a bureaucratic pipeline that is far more open to gene therapy than the United States.

[Image: DNA damage via Tom Ellenberger/Washington University School of Medicine]

For more stories like this, follow @fastcompany on Twitter. Find Neal Ungerleider, the author of this article, on Twitter.

Go here to see the original:
DNA Hacking Is Now Street Legal

Recommendation and review posted by Bethany Smith